<DOC>
	<DOCNO>NCT01374256</DOCNO>
	<brief_summary>Infections cause imipenem-resistant Acinetobacter baumannii associate high mortality morbidity . The treatment choice resistant pathogen limit . The objective present proposal evaluate effectiveness combination therapy imipenem sulbactam patient contract A. baumannii , correlate clinical effect vitro synergistic result .</brief_summary>
	<brief_title>Imipenem Sulbactam Treatment Imipenem-resistant Acinetobacter Baumannii Bacteremia</brief_title>
	<detailed_description>Acinetobacter baumannii increasingly report outbreak nosocomial infection intensive care unit , prolong length hospital stay result high attributable mortality . With intrinsic resistance many antimicrobial agent rapid acquirement resistance mechanism , resistance carbapenems , often accompany resistance multiple drug , emerge worldwide . The limited treatment choice include tigecycline , colistin , sulbactam . However , low serum level bacteriostatic nature tigecycline hamper application blood stream infection , one common presentation A. baumannii infection . The nephrotoxicity neurotoxicity intravenous colistin cause great concern critically ill patient whereas immediate bronchospasm inhalation significant clinical consequence report . Sulbactam use decade combination ampicillin well tolerate . However , emergence resistance strain discourage monotherapy severely ill patient make combination attractive choice . Combination sulbactam carbapenems good synergism A. baumannii elevate minimal inhibitory concentration ( MIC ) sulbactam and/or carbapenems animal model use A. baumannii high MIC sulbactam meropenem , survival rate high combination group sulbactam meropenem-treated alone group . The similar vivo bactericidal effect also observe combination imipenem sulbactam . Despite plenty vivo vitro study mention , clinical study limit . Besides , information regard correlation vitro synergistic effect carbapenem sulbactam clinical effect rarely mention . Therefore , study aim evaluate effectiveness combination therapy imipenem sulbactam patient contract A. baumannii , correlate clinical effect vitro synergistic result</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<criteria>elder 18 year old include bloodstream infection due A. baumannii regardless primary infection sit pregnancy lactation woman history serious allergy intolerance study drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>carbapenem</keyword>
	<keyword>sulbactam</keyword>
	<keyword>Acinetobacter baumannii</keyword>
</DOC>